Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

2.

A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone.

Blin J, Sette G, Fiorelli M, Bletry O, Elghozi JL, Crouzel C, Baron JC.

J Neurochem. 1990 May;54(5):1744-54.

PMID:
2182776
3.

[18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo.

Blin J, Pappata S, Kiyosawa M, Crouzel C, Baron JC.

Eur J Pharmacol. 1988 Feb 16;147(1):73-82.

PMID:
3259509
4.

Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.

Blin J, Baron JC, Dubois B, Crouzel C, Fiorelli M, Attar-Lévy D, Pillon B, Fournier D, Vidailhet M, Agid Y.

Brain. 1993 Jun;116 ( Pt 3):497-510.

PMID:
8513389
5.
6.

Development of fluorine-18-labeled 5-HT1A antagonists.

Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC.

J Med Chem. 1999 May 6;42(9):1576-86.

PMID:
10229627
7.

Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging.

Kapur S, Jones C, DaSilva J, Wilson A, Houle S.

Nucl Med Commun. 1997 May;18(5):395-9.

PMID:
9194079
8.
9.

Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.

Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1999 Jul;145(1):76-81.

PMID:
10445375
10.

Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography.

Arnett CD, Shiue CY, Wolf AP, Fowler JS, Logan J, Watanabe M.

J Neurochem. 1985 Mar;44(3):835-44.

PMID:
2579198
11.

Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.

Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PA.

Psychopharmacology (Berl). 1986;88(4):434-44.

PMID:
3010361
13.

Non-steady-state measurement of in vivo receptor binding with positron emission tomography: "dose-response" analysis.

Perlmutter JS, Kilbourn MR, Welch MJ, Raichle ME.

J Neurosci. 1989 Jul;9(7):2344-52.

14.

Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.

Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB.

Nucl Med Biol. 1999 Aug;26(6):601-8.

PMID:
10587097
15.

[In vivo study of central serotoninergic receptors in man using positron tomography].

Baron JC, Samson Y, Comar D, Crouzel C, Deniker P, Agid Y.

Rev Neurol (Paris). 1985;141(8-9):537-45. French.

PMID:
2935920
16.
17.

Two C-methyl derivatives of [11C]WAY-100635--effects of an amido alpha-methyl group on metabolism and brain 5-HT1A receptor radioligand behavior in monkey.

McCarron JA, Marchais-Oberwinkler S, Pike VW, Tarkiainen J, Halldin C, Sóvagó J, Gulyas B, Wikström HV, Farde L.

Mol Imaging Biol. 2005 May-Jun;7(3):209-19.

PMID:
15912425
18.

In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF.

Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN, Willemsen AT, Vaalburg W.

J Nucl Med. 2000 Nov;41(11):1830-5.

19.

Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: in vitro binding studies and positron emission tomography.

Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Luedtke RR, Kung MP, Kung HF, Lyons D, Morton TE.

Synapse. 1996 Dec;24(4):322-33.

PMID:
10638823
20.

A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans.

Yatham LN, Steiner M, Liddle PF, Shiah IS, Lam RW, Zis AP, Coote M.

Psychopharmacology (Berl). 2000 Sep;151(4):424-7.

PMID:
11026749

Supplemental Content

Support Center